Chugai Pharmaceutical Co., Ltd. (TYO: 4519)

Market Cap	10.50T
Revenue (ttm)	1.14T
Net Income (ttm)	386.96B
Shares Out	1.65B
EPS (ttm)	235.15
PE Ratio	27.14
Forward PE	27.20
Dividend	82.00 (1.28%)
Ex-Dividend Date	Jun 27, 2024

Volume	2,286,100
Open	6,544.00
Previous Close	6,444.00
Day's Range	6,331.00 - 6,556.00
52-Week Range	4,572.00 - 7,869.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu,...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2023, Chugai Pharmaceutical's revenue was 1.11 trillion, a decrease of -11.79% compared to the previous year's 1.26 trillion. Earnings were 325.47 billion, a decrease of -13.08%.